加载中
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
前收盘价
US$1.90
−US$0.10 · -5.00%
盘中时间采用ET。市场数据可能有所延迟。
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
日内区间
当前US$1.90
52周区间
当前US$1.90
盘中时间采用ET。市场数据可能有所延迟。
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
日内区间
当前US$1.90
52周区间
当前US$1.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 40.82万 USD | 67.4万 USD | 74.3万 USD | 81万 USD | 85.3万 USD |
| 销货成本 | 2.42万 USD | — | — | — | — |
| 毛利 | 38.4万 USD | 67.4万 USD | 74.3万 USD | 81万 USD | 85.3万 USD |
| 研究与开发 | 674.61万 USD | 575.7万 USD | 598.3万 USD | 776.3万 USD | 985万 USD |
| 销售、一般及管理费用 | 366.69万 USD | 304.7万 USD | 295.5万 USD | 314.3万 USD | 384.5万 USD |
| 营业费用 | 1041.3万 USD | 880.4万 USD | 893.8万 USD | 1090.6万 USD | 1369.5万 USD |
| 利息收入 | 28.63万 USD | 29.1万 USD | 50.6万 USD | 22.2万 USD | 2.4万 USD |
| 利息支出 | 1.41万 USD | 1.4万 USD | 1.4万 USD | 7.7万 USD | 1.8万 USD |
| 折旧和摊销 | 2.42万 USD | 7000 USD | 1.5万 USD | 1.4万 USD | 1.4万 USD |
| 营业利润 | −1002.89万 USD | −813万 USD | −819.5万 USD | −1009.6万 USD | −1284.2万 USD |
| 净利润 | −990.6万 USD | −788万 USD | −763.4万 USD | −1017.3万 USD | −1259.5万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年1月5日 | 1:20 | — | — |
股票拆分 | 2023年1月9日 | 1:10 | — | — |
股票拆分 | 2019年5月10日 | 1:15 | — | — |
已生效 2026年1月5日
1:20
已生效 2023年1月9日
1:10
已生效 2019年5月10日
1:15
报告持有此股票敞口的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM171.97万0.01%175.23亿 USD0.07%US$52.21+1.32%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX48万0.07%6.65亿 USD0.65%US$71.64+1.00%
State Street SPDR S&P Emerging Asia Pacific ETFGMF33.09万0.08%4.22亿 USD0.49%US$154.60.00%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM9.44万0.01%18.02亿 USD0.09%US$87.44+0.55%State Street SPDR Portfolio Emerging Markets ETFSPEMState Street SPDR S&P Emerging Markets Small Cap ETFEWXState Street SPDR S&P Emerging Asia Pacific ETFGMFState Street SPDR Portfolio MSCI Global Stock Market ETFSPGMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
